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The Food & Drug Administration (FDA) convened a workshop to discuss clinical trial design 
challenges and considerations related to the treatment of non-tuberculous mycobacterial 
pulmonary disease (NTM-PD), to include topics such as clinical trial endpoints, duration, and 
populations.  Here the clinicians participating in the meeting provide their interpretation of the 
discussion, which included FDA and industry representatives.  The treatment of NTM-PD 
typically includes multiple antibiotics for a prolonged period, can be difficult to tolerate, and 
there is great need for new treatment options.  Most individuals have a microbiologic response to 
therapy, but currently there is a lack of data correlating decreasing bacillary load with patient-
reported outcomes or measured functional improvement.  Accordingly, trial designs for new 
therapeutics should incorporate both microbiologic and clinical outcome measures and select 
appropriate study candidates with capacity for measurable change of such outcome measures.  
The need for shorter study designs, early primary endpoints, and placebo control arms was 











The prevalence of pulmonary nontuberculous mycobacteri l (NTM) infections has 
increased considerably in the last decade(1).  Published guidelines offer recommendations for 
diagnosis and treatment(2), but currently there are only two products approved by the United 
States Food and Drug Administration (FDA) to treat NTM, amikacin liposome inhalation 
suspension for the treatment of refractory infection due to Mycobacteria avium complex (MAC) 
and macrolides for the treatment of disseminated MAC infection in patients with human 
immunodeficiency virus. New therapies for NTM pulmonary disease (NTM-PD) are needed to 
improve clinical outcomes.  Achieving this goal will require repurposing existing medications 
and/or the development of novel drugs.  Developing a  evidence base for new drugs to meet 
regulatory requirements necessitates clinical trialdesigns that can demonstrate efficacy and 
safety in studies that are feasible and ethical.  The FDA convened a workshop in April 2019 to 
discuss clinical trial design challenges and considerations related to the treatment of NTM-PD, to 
include topics such as trial endpoints, duration, and populations.  In this document, the clinicians 
participating in the hearing report the challenges and areas of controversy, as well as proposed 
solutions, highlighted during this meeting.    All invited panelists are listed in the 
Acknowledgements.   
Current State of Diagnosis and Treatment of NTM-PD 
The reader is referred to other sources for a more c mplete description of the 
epidemiology, risk factors, and treatment outcomes in NTM-PD(2).  The diagnosis of NTM-PD 
is based upon clinical symptoms, radiographic findings, and the identification of NTM in 
cultures of respiratory specimens(2).  Signs and symptoms may be pulmonary (e.g. persistent 








fatigue).  Radiographic features include nodular or tree-in-bud densities, consolidation, and 
cavities, frequently in the setting of bronchiectasis or emphysema. Of key importance is that 
these signs and symptoms are not specific for NTM-PD and it is common that patients 
experience symptoms for years before a diagnosis of NTM-PD is made(3). Nearly 200 different 
NTM species have been identified, although many have not been associated with disease in 
humans. MAC, which includes M. avium, M. intracellulare, and M. chimaera is the most 
frequently isolated group of NTM pathogens, and causes 80-90% of all NTM-PD in the US, but 
there are other NTM known to cause disease in humans as well, especially M. abscessus(2).  
Although the principles discussed during this workshop are applicable to other NTM, most of the 
discussion focused on MAC-PD. 
There are published recommendations for the management of NTM-PD(2).  When anti-
mycobacterial antibiotics are deemed necessary, the treatment generally involves multiple 
medications administered for a prolonged period.  The guidelines recommend treatment with the 
intent to achieve long-term sputum culture conversion, defined as consistently negative 
respiratory cultures, implying successful reduction in bacterial burden and, potentially, cure.  
Accordingly, antibiotic treatment is recommended for a full 12 months after sputum culture 
conversion.  The success of treatment varies based on the specific NTM species being treated, 
the amount of structural lung disease (e.g. cavities), the antibiotics used to treat the infection, and
the ability of the patient to remain on that treatment(2).  Best case scenarios have reported 
culture conversion of greater than 80% for MAC infections, but a recent systematic review and 
meta-analysis reported a sustained conversion rate of 65% in those who took a three-drug 








therapies.  Further, 25-50% or more patients suffer mic obiologic recurrence due to relapse or 
reinfection, generally within three years of stopping antibiotic therapy(5-7). 
Monitoring patients for evidence of treatment response or the occurrence of adverse 
reactions during therapy includes periodic microbiologic assessment, radiologic evaluations, and 
assessment of patient subjective symptoms and functional status.  Clinical experience suggests 
that most patients experience improvement in their cough and fatigue during therapy(8), and 
some patients have improvement in other aspects of their symptoms (e.g. improved exercise 
tolerance, less dyspnea)(9).  Although long-term treatment is planned, many patients will 
experience improvement in their symptoms within the first few months of therapy.  Adverse 
effects of medications can diminish quality of life, and it is not uncommon to stop specific 
antibiotics within a regimen and/or start new ones if a regimen is not being tolerated(10).   
Development of Antibacterial Drugs for NTM: A Patient Perspective 
Patient perspectives regarding treatment of NTM-PD have been obtained from a number 
of sources.  An NTM Research Consortium Workshop engaged patients to define research 
priorities and features of study design(11).  The priorities identified with respect to treatment of 
infection included promoting quality-of-life measures for assessing the effectiveness of treatment 
and a need to reduce the burden of antibiotic treatm n .  Prior to this workshop NTM Info & 
Research, a non-profit US organization advocating for patients with NTM-PD, conducted a 
survey of patients, of whom 84% had been treated with antibiotics (Table 1).  There is wide 
disparity in the types of symptoms (respiratory vs. systemic) and considerable overlap of 
symptoms attributed to the infection and the treatmnt.  There was clear interest in the 
microbiologic endpoint as noted when subjects were asked: “if your treatment could change one 








preference was for culture conversion.  This likely correlates with the patients’ view that the 
objective of treatment is cure with return of normal health and cessation of medications, and the 
only path to cessation of medication is associated with culture conversion. 
Development of Antibacterial Drugs for NTM: A Regulatory Perspective 
The FDA mandate for development of new drugs is the demonstration of sufficient safety 
and efficacy, the latter defined as improving how a patient feels, functions, and/or survives.  
Accelerated approval of a drug was recently granted based on sputum culture conversion, but 
there are limited data evaluating the relationship between this microbiological endpoint and 
clinical benefits.  A review of the literature was conducted to establish whether culture 
conversion could be used as a surrogate endpoint for clinical benefit.  Although there were hints 
of an association there was no definitive evidence to support surrogacy of the microbiologic 
endpoint.  Retrospective, non-randomized studies suggested higher mortality rates in patients 
with MAC-PD who remained culture positive despite trea ment compared to those who convert 
to culture negative(12, 13).  A retrospective analysis of treatment response in a cohort of 
nodular/bronchiectatic MAC-PD patients showed both improvement in semi-quantitative sputum 
culture scores and sputum conversion correlated with symptomatic improvement, especially 
cough(8). However, studies were from single centers or included a specific subtype of MAC-PD 
which limits generalizability to the overall population.  A primary limitation of using 
microbiologic endpoints as surrogate for clinical benefit is the lack of prospective randomized 
control trial data examining this idea.  Two studies of treatment refractory MAC-PD suggested 
that culture conversion correlates with improvements i  6-minute walk (6MW) test, although 
neither study demonstrated an association between conversion and symptoms or quality of life as 








These observations do not mean that culture conversion does not correlate with improved 
clinical outcomes; rather it means only that existing data have not clearly demonstrated that the 
microbiological outcome can serve as a surrogate marker for clinical benefit as defined by “feels, 
functions, or survives”.  The cumulative clinical exp rience of the expert panelists suggests that 
sputum culture conversion is a necessary endpoint fr the assessment of treatment response and 
that it does associate with improved symptoms.  Thelack of data may be due to the orphan 
nature of the condition, limited “natural history” data on what happens to symptoms of patients 
that are not treated, overlapping symptoms with underlying lung diseases (e.g. bronchiectasis), 
and symptoms associated with the treatment itself. The heterogeneity of symptoms in NTM-PD 
also makes the consistent demonstration of benefit challenging, particularly as currently used 
instruments to assess patient reported outcomes were not designed for use in patients with NTM-
PD. Also, successful treatment does not implicitly mean cure, or eradication of the infection; and 
it may be necessary to establish a definition of disease control or low disease activity.  
Regardless, the panel overwhelmingly reiterated that for the treatment of an infectious disease a 
decrease in the burden of infection (i.e. a decrease in bacillary load as defined by sputum 
microbiological results) is an essential aspect of decision making for clinical care and is therefore 
a critical outcome in clinical trials.  
Trial Design Considerations 
Patient Population Heterogeneity 
Previous studies have included heterogeneous subject populations (Table 2), but subjects 
recruited for a study should have disease manifestations that have the potential to respond to the 
treatment, that is, disease that is neither so indole t nor far advanced that treatment effects would 








predicting a response to treatment; patients with CF were excluded from a Phase 3 study(14) 
based on previous results in which the few CF patients studied did not achieve culture conversion 
(9).  Patients with advanced structural lung disease, e pecially cavities, are thought to be less 
likely to achieve culture conversion when compared to those patients with nodules or 
bronchiectasis without cavities(15).  The pathogen and its susceptibility, defined by standard 
laboratory methods, may also predict responsiveness to treatment.  Macrolide resistant MAC is 
associated with a lower rate of culture conversion(4).  Of note, subjects whose MAC showed a 
high level of amikacin resistance were excluded from studies of amikacin liposome inhalation 
suspension(14).  Finally, the treatment history is highly relevant.  Studies have enrolled subjects 
who met criteria for “treatment refractory” disease (i. . defined as positive cultures despite >6 
months of a guideline-based multi-drug regimen), but these are different from a population naïve 
to antibiotic treatment.  Even in the treatment-refractory cohorts, there were widely disparate 
treatment regimens and durations of treatment.  Although there are recommendations for drug 
regimens in MAC-PD, evidence suggests they are infrquently followed in actual clinical 
practice(16, 17).   
Enriching for responders 
Subjects enrolled into a trial should have baseline measures of clinical outcomes that 
suggest they could demonstrate improvement (or worsening), or in other words, they should have 
the capacity to change.  In one study there was a wide range of baseline symptom scores and 
functional status (as measured by 6MW)(14).  Some patients had relatively few symptoms (i.e. 
normal score) and a 6MW distance in the normal range for healthy subjects, therefore leaving 
little or no room for symptomatic or functional improvement.   








Although treatment guidelines recommend a duration of 12 months following culture 
conversion, this recommendation does not mean that a drug assessment requires a study of this 
duration.  If a drug is efficacious, a clinical and microbiologic response should be expected 
within a much shorter period in most instances.  Clinicians on the panel suggested strong 
consideration for limiting trials to 3-6 months or even less, as they desire the opportunity to 
change treatment if there is a perceived lack of efficacy.  Therefore, if a study is to be based 
upon clinical outcomes then it was felt that the primary endpoint should be assessed earlier than 
the end of treatment. The observation, described above, that symptoms often improve in the first 
few months of therapy suggest that symptomatic improvements in short term studies would be 
demonstrable.  This presumes that the outcome measure is not caused by the drug (e.g. cough 
due to inhaled therapies).  Long study durations also increase the likelihood of significant 
changes to background regimens that will affect assessment of both efficacy and safety of the 
studied drug.   
Comparator and companion drugs 
The study of a drug requires comparison to something, whether an active comparator or a 
placebo, in order to determine safety and efficacy.  For the subjects who have treatment-naïve 
NTM-PD several options could be considered.  Monotherapy could be compared to a placebo, 
but depending on the drug and its mechanism, there may be discomfort using a single drug 
against NTM for fear of selecting for resistance, although perhaps this fear could be overcome 
with short study durations.  Alternatively, the study drug could be combined with others in order 
to mitigate potential generation of drug resistance and compared to a placebo regimen.  This 
option perhaps is the most acceptable, as we often do not start patients needing therapy for 3-6 








obtain microbiologic information, adopt pulmonary hgiene measures, and assess for disease 
progression.  However, periods of placebo exposure for greater time-periods could be 
problematic for patient safety, but the allowance of rescue therapy should mitigate such concern. 
Another option is to use the investigational drug or placebo as an add-on or replacement of a 
drug in a multi-drug regimen to show “incremental benefit” of the drug.  This approach requires 
a much greater number of patients and much longer study duration to have sufficient statistical 
power to show a benefit over the comparator regimen (assuming it is an active and efficacious 
comparator).  Lastly, patients with treatment-refractory disease could have the study drug or 
placebo as an add-on to a failing standard regimen. 
This issue raises questions regarding what defines acceptable companion therapy for 
NTM-PD.  All medications have potential adverse effects that may be intolerable or toxic.  They 
may interact with the subject’s other medications preventing use of some antibiotics.  Therefore, 
it cannot be presumed that all subjects would be treated with the same medications.  
Combinations would need to be justified by evidence that supports efficacy, safety, or prevention 
of resistance.   
Study outcome measures 
As noted earlier, there is a need for a clinical outc me measure that satisfies regulatory 
requirements and patient expectations as well.  Currently there is no validated instrument for the 
specific purposes of NTM treatment trials.   In order to assess how a patient “feels” the preferred 
instrument is one that assesses patient-reported outcomes (PRO).  A major challenge is the 
heterogeneity of symptoms reported by patients; for some cough is the primary symptom while 
for others it may be fatigue, and to include both types of patients in a study the instrument must 








Georges Respiratory Questionnaire (SGRQ) and the Quality of Life-Bronchiectasis (QOL-B), 
and each have demonstrated improvement while on treatment(18, 19) although neither has 
demonstrated obvious differences associated with treatment in controlled clinical trials(9, 14).  
Neither of these instruments were designed for this purpose, but perhaps they could be refined to 
be more sensitive to change with respect to NTM-PD, or it may be necessary to develop new 
instruments.  A recent publication evaluating the QOL-B with an NTM module in an 
observational cohort found improvement to correlate wi h culture conversion in MAC-PD 
patients(19).  The data suggest potential utility of these PROs and they should be evaluated in 




These instruments must also be sensitive to identifyi g when symptoms are attributed to 
the underlying condition or the treatment itself.  For example, systemic antibiotics could cause 
fatigue and inhaled antibiotics are known to provoke cough(14).  It is difficult to assess when the 
symptom is both an adverse event and a treatment outcome.  This observation raises the 
necessity for careful consideration regarding the timing of these measurements, whether while on 
therapy or some time-period after their discontinuation.  A limitation of quality of life measures 
is that they are usually performed at two fixed time points (e.g. baseline and a defined time point 
during treatment).  In the context of NTM-PD, some symptoms may increase while on treatment 
due to the impact of drugs, but earlier sputum culture conversion could result in a shorter 
treatment period and, therefore, shorter duration of treatment-related symptoms.  Treatment-








what to expect.  Patients typically understand and welcome the concept of “short-term pain for 
long-term gain”; our current methods of assessment of PROs will need to address this concept as 
well. 
Although PROs are preferred, there are clinician-repo ted outcomes and performance 
outcomes that may also be relevant.  Radiographic changes have been reported in the literature 
but there is no validated scoring method that has been tested in NTM-PD treatment trials.  Also, 
radiographic changes do not meet the definition of efficacy in terms of “feels, functions and 
survives”. The 6MW test has been used in studies demonstrating improvement with active 
treatment in a smaller trial but not in the larger trial(9, 14).  Interestingly, however, the measure 
was significantly correlated with culture conversion n both studies.  The 6MW test measures 
physical functioning but it may not capture the totality of treatment response in NTM-PD; many 
patients do not experience breathlessness or functional decline.  Since the antibiotics would not 
be expected to directly improve cardiopulmonary performance, the 6MW test might be relevant 
only for subjects who have demonstrated a significant reduction in infection (e.g. bacterial 
burden, culture conversion).  Finally, it may prove useful to consider composite endpoints, based 
on a combination of individual endpoints, for drugs that may benefit patients in several ways, as 
has been used in other chronic inflammatory conditions (e.g. rheumatoid arthritis) that may 
provide reflections of disease activity that are sensitive to change(20). 
Since this is treatment of an infectious disease, there will be continued interest in 
microbiological endpoints.  Successful treatment of NTM-PD by any definition cannot be 
accomplished without control of the organism in the lung.  If microbiological measures could be 
demonstrated to serve as a surrogate measure, this might allow for shorter studies.  The onus is 








culture conversion or other microbiological endpoints on relevant clinical outcomes.  Studies 
have primarily used culture conversion as the main interpretation of the antibiotic effect, but 
other measures may reflect bacterial burden.  Semiquantitative culture results have correlated 
with symptomatic and radiographic improvement, as well as culture conversion(8).  Time to 
positivity in broth cultures can predict microbiologic response to treatment of tuberculosis(21) 
but this has not been studied in NTM infection.  Molecular techniques are increasing available 
and may provide alternatives to culture based assessment of bacterial burden in the future. 
A novel concept would be to demonstrate reduction in bacterial burden that associates 
with clinical benefits but does not eradicate the pathogen.  Since eradication is infrequent given 
our current therapeutic armamentarium, the notion of suppressive therapy is attractive.  
Designing trials with suppression of pathogens as a goal may still achieve desired clinical 
outcomes with long periods of life without disease ctivity (i.e. remission or low disease 
activity), as is currently done with inhaled antibiotics for the treatment of chronic Pseudomonas 
aeruginosa infection in CF patients(22).  Since many patients wi h refractory disease remain on 
antibiotics for years, it would seem that clinicians and patients have already adopted this as an 
acceptable treatment paradigm.   
Monitoring during the study 
A key challenge to monitoring during a study is theconsiderable discomfort expressed by 
clinicians with blinding to microbiological data during a prolonged study.  Blinding to sputum 
culture results is done to avoid the impact the results may have on clinician decision-making and 
possibly influencing patient-reported health-related quality of life.  In order to maintain 







cannot be of long duration.  If persistence of NTM in cultures drives treatment decisions, then 
eventually clinicians will need to know the data if they perceive that patients are not improving. 
Conclusions 
The clinicians on the panel concluded that NTM-PD is a condition in great need of new 
treatment options.  Considerable knowledge has accrued in the past several years that has 
clarified the challenges that must be addressed in trial designs.  These include selection of 
appropriate candidate subjects for clinical trials as well as proper outcome measures.  There will 
always be interest in the microbiological endpoints but there is a need to define a clinical 
outcome measure to be used in NTM treatment trials.  We are in agreement that long duration 
trials (i.e. longer than 3-6 months) are not acceptable, and clinicians expressed a willingness to 
tolerate trials up to six months with placebo and blinding to microbiologic data, after which they 
would want to be able to amend the treatment regimen if there is not clear evidence of 
improvement.  
The next step is to validate novel or existing PROs to be used in NTM-PD treatment 
trials.  Such instruments must identify patients whose symptoms could respond to antibiotic 
therapy and how those symptoms correlate with microb ol gic changes.  Refinement of PROs 
will have to occur in prospective observational trials and eventual testing of the PROs in clinical 
trials.  Finally, there could be development of novel functional measures (e.g. wearable 
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Table 1: Key findings from surveys of patient with NTM-PD.   Results from 465 respondents.  
Survey conducted by NTMinfo. 
Most common symptoms associated with their condition 
• Fatigue 77% 
• Cough productive of sputum 71% 
• Dyspnea 67% 
• Coughing without sputum 51% 
• Night sweats 49% 
• Weight loss 43% 
• Hemoptysis 34% 
• Lack of appetite 33% 
• Chest pain 32% 
• Anxiety 32% 
Preferences for treatment outcomes 
• Improved quality of life 97% 
• Increased energy/less fatigue 84% 
• Culture conversion 72% 
• Reduce coughing 53% 
• Improvement in dyspnea 42% 
• Repair lung damage 28% 
• Improve lung function 27% 
• Reduce progression of disease 21% 
• Reduce mucus/sputum 20% 
Most common reported adverse effects of treatment 
• Fatigue 
• Dry mouth 
• Cough 
• Tinnitus 




• Cognitive dysfunction 










Table 2. Heterogeneous factors complicating NTM clin cal trials 
 
Subject factors 
• Underlying disease and co-morbidities 
• History of treatment of NTM infection (e.g. naïve, r fractory to treatment) 
• Radiographic features (e.g. nodules, presence of cavities) 
• Pathogen and antimicrobial susceptibility 
Clinical endpoints 
• Baseline symptoms (i.e. able to detect change?) 
• Baseline functional status (e.g. 6MW distance) 
Study design parameters 
• duration of the study 
• superiority vs. non-inferiority statistical analysis 
• blinding and monitoring 
• companion drugs 
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